Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 23
2005 72
2006 87
2007 102
2008 113
2009 129
2010 117
2011 155
2012 167
2013 235
2014 367
2015 435
2016 562
2017 595
2018 604
2019 662
2020 878
2021 899
2022 845
2023 872
2024 894
2025 1008
2026 513

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,730 results

Results by year

Filters applied: . Clear all
Page 1
Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy.
Roessler N, Nowicka Z, Miszczyk M, Calleris G, Dematteis A, Vetterlein MW, Albisinni S, Van Der Poel HG, Cathcart P, Cacciamani GE, Gill IS, Persad RA, Joniau S, Sanchez-Salas R, Smith JA Jr, Karnes RJ, Ahmed ME, Rajwa P, Tilki D, Shariat SF, Gontero P, Marra G; Young Academic Urologists Prostate Cancer Working Party. Roessler N, et al. BJU Int. 2026 Jun 15. doi: 10.1111/bju.70352. Online ahead of print. BJU Int. 2026. PMID: 42298374
PATIENTS AND METHODS: Evaluable patients were selected from a retrospective dataset, resulting in a cohort of 879 patients with recurrent, non-metastatic, hormone-sensitive prostate cancer treated with sRP at 13 centres. ICE surrogacy was evaluated using a two-stage approa …
PATIENTS AND METHODS: Evaluable patients were selected from a retrospective dataset, resulting in a cohort of 879 patients with recurrent, n …
Limitations in diagnostics and quantification of small lesions with low uptake in the clinical context of prostate 18F/68Ga-PSMA PET/MRI.
Lindemann ME, Jentzen W, Küper A, Costa PF, Gratz M, Umutlu L, Nagarajah J, Nekolla SG, Rausch I, Herrmann K, Quick HH, Kersting D. Lindemann ME, et al. EJNMMI Phys. 2026 Jun 15. doi: 10.1186/s40658-026-00902-3. Online ahead of print. EJNMMI Phys. 2026. PMID: 42298255
PURPOSE: The aim of this study was to investigate the limits of diagnostics and therapy planning for patients with prostate cancer using non-time-of-flight (18)F/(68)Ga-PSMA PET/MRI under clinically challenging imaging conditions with small lesion sizes and low uptake. ...
PURPOSE: The aim of this study was to investigate the limits of diagnostics and therapy planning for patients with prostate cancer us …
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma.
Lombardi P, Ramon-Gil E, Raja RQ, Brunetti L, Manfredi GF, Zhou Z, Merces G, Cappuyns S, Fulgenzi CAM, D'Alessio A, Torkpour A, Celsa C, Stefanini B, Yang H, Crowley F, Marron TU, Saeed A, Pinter M, Scheiner B, Huang YH, Lee PC, Nishida N, Po-Ting Lin R, Dalbeni A, Vivaldi C, Masi G, Rohlen N, von Felden J, Kaseb A, Galle PR, Kudo M, Hsu WF, Rimassa L, Parisi A, Kelley RK, Toyoda H, Pirisi M, Jabar F, Rakaee M, Cabibbo G, Cammà C, Piscaglia F, Hwang S, Shin DJ, Li M, Dekervel J, Guerra N, Meyer T, Reeves HL, Bengsch B, Daniele G, Mann DA, Chon HJ, Leslie J, Pinato DJ. Lombardi P, et al. J Hepatol. 2026 Jun 15:S0168-8278(26)02605-X. doi: 10.1016/j.jhep.2026.05.018. Online ahead of print. J Hepatol. 2026. PMID: 42297215
PRef was defined by Society for the Immunotherapy of Cancer (SITC) criteria. We performed a multi-parametric analysis of pre-treatment tumour tissue, including machine learning-based quantification of tumour-infiltrating lymphocytes, imaging mass cytometry (IMC) and RNA se …
PRef was defined by Society for the Immunotherapy of Cancer (SITC) criteria. We performed a multi-parametric analysis of pre-treatmen …
Plant-Based Diets, Ultra-Processed Foods, and Risks of Mortality and Major Chronic Diseases: A Prospective Cohort Study.
Thompson AS, Jennings A, Bondonno NP, Cassidy A, Kühn T. Thompson AS, et al. Lancet Reg Health Eur. 2026 Jun 5;67:101736. doi: 10.1016/j.lanepe.2026.101736. eCollection 2026 Aug. Lancet Reg Health Eur. 2026. PMID: 42294356 Free PMC article.
Participants were followed for 8.3-10.5 years for all-cause mortality and incident T2DM, CVD, and cancer. Multivariable Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs). FINDINGS: Among 124,836 participants (mean [SD] age 56.2 [7.8] years; 55.8% …
Participants were followed for 8.3-10.5 years for all-cause mortality and incident T2DM, CVD, and cancer. Multivariable Cox models es …
Survival Differences of Localized Papillary Renal Cell Carcinoma in African Americans vs. European Americans.
Filzmayer M, Polverino F, Petix M, Quarta L, Orlandi F, Goyal JA, Longo N, Carmignani L, Briganti A, Micali S, Shariat SF, Humke C, Traumann MI, Wenzel M, Saad F, Chun FKH, Karakiewicz PI. Filzmayer M, et al. J Racial Ethn Health Disparities. 2026 Jun 13. doi: 10.1007/s40615-026-03038-3. Online ahead of print. J Racial Ethn Health Disparities. 2026. PMID: 42288708
Other-cause mortality (OCM) at 120 months after nephrectomy was higher in African Americans (29.0% vs. 22.2%), while cancer-specific mortality (CSM) did not differ (11.0% vs. 10.3%) between the two populations. ...
Other-cause mortality (OCM) at 120 months after nephrectomy was higher in African Americans (29.0% vs. 22.2%), while cancer-specific …
Outcome-driven dosimetry optimization for [177Lu]Lu-PSMA-617 radiopharmaceutical therapy: proof of concept on single time point dosimetry optimization.
Hu J, Seifert R, Gomes CV, Chen Y, Liu Y, Jutidamrongphan W, Amon M, Wang J, Xue S, Rominger A, Afshar-Ormieh A, Shi K. Hu J, et al. Eur J Nucl Med Mol Imaging. 2026 Jun 13. doi: 10.1007/s00259-026-07936-w. Online ahead of print. Eur J Nucl Med Mol Imaging. 2026. PMID: 42287389
In patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [(177)Lu]Lu-PSMA-617 RPT, we explored an outcome-driven dosimetry optimization strategy by comparing MTP and single-time-point (STP) dosimetry, and identifying optimal time-points (TPs) f …
In patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [(177)Lu]Lu-PSMA-617 RPT, we explored an outcom …
Sex Differences in Cancer and Cardiotoxicity: Mechanisms, Outcomes, and Clinical Implications Across Solid and Hematological Malignancies.
Keramida K, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Dent S, Drakaki A, Fuster JJ, Mamas MA, Okwuosa T, Scarfo L, Van Der Meer P, Yang EH, Lopez-Fernandez T. Keramida K, et al. Cancers (Basel). 2026 May 22;18(11):1677. doi: 10.3390/cancers18111677. Cancers (Basel). 2026. PMID: 42279262 Free PMC article. Review.
Sex differences influence cancer incidence, treatment response, and susceptibility to cardiovascular toxicity. Males exhibit higher rates and poorer outcomes in most non-sex-specific cancers, while females more frequently experience treatment-related adverse events, includ …
Sex differences influence cancer incidence, treatment response, and susceptibility to cardiovascular toxicity. Males exhibit higher r …
Spatial biomarker discovery via interpretable semantic learning in histopathology.
Liang J, Jiang X, Reitsam NG, Lenz T, Zhang L, Gustav M, Carrero ZI, Muti HS, Neidlinger P, Clusmann J, Žigutytė L, Sainath V, Wolf F, Boardman LA, French AJ, Goode EL, Gsur A, Brezina S, Gunter MJ, Steinfelder R, Harrison T, Peters U, Phipps AI, Quirke P, West NP, Hoffmeister M, Brenner H, Wankhede D, Jonnagaddala J, Hawkins N, Ward RL, Fountzilas E, Papadopoulou K, Fountzilas G, André T, Taieb J, Emile JF, Svrcek M, Kong L, Kather JN. Liang J, et al. Cancer Cell. 2026 Jun 11:S1535-6108(26)00259-X. doi: 10.1016/j.ccell.2026.05.014. Online ahead of print. Cancer Cell. 2026. PMID: 42276049 Free article.
Spatial biomarkers are critical for precision oncology but remain challenging to systematically discover due to the complexity of whole-slide images. ...Applied to 7,000 patients with colorectal cancer across 11 cohorts, PathPrism uncovered hundreds of biomarkers pr …
Spatial biomarkers are critical for precision oncology but remain challenging to systematically discover due to the complexity of who …
8,730 results